PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,775.00
Bid: 1,771.00
Ask: 1,771.50
Change: -8.50 (-0.48%)
Spread: 0.50 (0.028%)
Open: 1,773.50
High: 1,779.00
Low: 1,764.50
Prev. Close: 1,783.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Cooler US CPI provides shot in the arm for stocks

Wed, 10th Aug 2022 16:57

(Alliance News) - Stocks in London were buoyed on Wednesday by softening US inflation, raising hopes that the Federal Reserve will be less aggressive in its tightening when it meets next month.

"We don't often get pleasant surprises surrounding the US inflation data so July's numbers are something to be cherished," said ING.

The FTSE 100 index closed up 18.96 points, or 0.3%, at 7,507.11. The FTSE 250 ended up 385.60 points, or 1.9%, at 20,298.00, and the AIM All-Share closed up 5.03 points, or 0.6%, at 919.78.

The Cboe UK 100 ended up 0.4% at 750.90, the Cboe UK 250 closed up 2.1% at 17639.76, and the Cboe Small Companies ended up 0.3% at 14334.41.

In European equities on Wednesday, the CAC 40 in Paris ended up 0.5%, while the DAX 40 in Frankfurt ended up 1.2%.

Wednesday started off slow for stocks in Europe, posting modest losses, but US inflation data released in the afternoon saw major indices spike.

Annually, US consumer prices were up 8.5% in July, slowing from the 9.1% rise seen in June. Market consensus, according to FXStreet, had seen inflation easing only to 8.7% for July.

Versus the previous month, July's prices were entirely flat, slowing from the 1.3% rise in June and behind the market consensus of 0.2%.

Stripping out food and energy, prices were up 0.3% in July from the month before, which the US government noted was a smaller increase recorded in April, May, or June. The July increase matched consensus. On annual basis, core prices rose 5.9%. The annual core CPI rise also was in line with forecasts.

Expectations for the Fed's September meeting were scaled back as analysts digested Wednesday's figures.

On Tuesday, 68% of market participants were expecting the Fed to carry out another 75 basis point rate hike at September's meeting, up from 43% a month before. Following Wednesday's inflation data, however, the probability of a 75 basis point hike stood at just 38%, with the majority view now for the Fed's hiking size to moderate to a half-point.

"This is not yet the meaningful decline in inflation the Fed is looking for. But it's a start and we expect to see broader signs of easing price pressures soon," said Capital Economics.

The dollar fell sharply after US CPI. The pound was quoted at USD1.2253 at the London equities close Wednesday, jumping from USD1.2086 at the close on Tuesday.

The euro stood at USD1.0349 at the European equities close Wednesday, rising against USD1.0223 at the same time on Tuesday. Against the yen, the dollar was trading at JPY132.41, down compared to JPY134.96 late Tuesday.

Gold was quoted at USD1,799.85 an ounce at the London equities close Wednesday, up against USD1,793.82 at the close on Tuesday due to dollar weakness.

Brent oil was quoted at USD94.77 a barrel at the London equities close Wednesday, down from USD97.62 late Tuesday.

Stocks in New York roared ahead, with the DJIA soaring 1.7% in late morning trade, the S&P 500 index rising 2.0%, and the Nasdaq Composite jumping 2.5%.

The FTSE 100's gains were more modest, however, on account of the stronger pound holding back the overseas earnings-heavy index.

The blue-chip index was also dragged down by GSK spin-off Haleon, ending down 8.1% at 279.50 pence, with the stock now down 15% from its IPO price of 330p. GSK, which remains a shareholder in Haleon, closed down 5.5%.

Utilities were lower as the risk-on tone shifted investor favour towards growth stocks. Centrica ended down 5.5% and SSE was down 2.4%, while telecommunications firm BT fell 1.3%. In contrast, tech stock and online grocer Ocado rose 6.6%.

At the top of the FTSE 100 was Admiral, rising 13%, with the insurer reporting a "solid set" of resuts despite a first-half profit fall.

Revenue in the six months to June 30 rose 5.7% year-on-year to GBP1.85 billion from GBP1.75 billion. Total UK premiums written, which comprises its motor, home and travel insurance units, was 2.8% higher year-on-year at GBP1.27 billion from GBP1.23 billion.

Group pretax profit fell 48% year-on-year to GBP251.3 million from GBP482.2 million. Compared to pre-Covid times, however, pretax profit was up 19%. Pretax profit was in line with consensus, broker Peel Hunt noted.

Fellow insurer Aviva rallied 12% as it unveiled plans for a share buyback amid confidence in its prospects.

In the six months to June 30, its IFRS loss widened to GBP633 million from a GBP198 million loss a year prior. Aviva explained that this "largely" reflects adverse market movements and has no impact on capital or cash remittances. Adjusted operating profit rose 14% to GBP829 million from GBP725 million.

Aviva declared an interim dividend of 10.3p per share, rising 40% from 7.35p a year earlier, in line with its full year guidance of around 31.0p per share. The interim dividend is worth a total of GBP289 million.

Looking ahead, Aviva said it is confident of its outlook for 2022, despite a challenging market backdrop. The insurer also said it expects to start a share buyback programme when its 2022 full year results are announced.

In the FTSE 250, TP ICAP rose 14% after the interdealer broker saw interim pretax profit more than double to GBP72 million from GBP28 million. TP ICAP upped its dividend by 13% to 4.5p per share from 4.0p a year prior.

4imprint rose 11% after reporting a surge in interim profit and a double-digit rise in interim revenue as total orders increased. The London-based marketer of promotional merchandise booked a 58% rise in revenue to USD515.5 million and pretax profit multiplied to USD43.9 million from USD3.4 million.

Elsewhere, S&U rose 12% after saying both its motor and property bridging divisions continue to outperform its internal expectations.

The motor and property bridge loan provider said its current receivables stand at GBP370 million, up from GBP340 million in May. S&U added that profitability in the six months to July 31 exceeded the same period last year.

In Thursday's UK corporate calendar, there are half-year results from Chilean miner Antofagasta, soft drinks bottler Coca-Cola HBC, gambling firm Entain and investment manager M&G.

The economic calendar has Irish inflation at 1100 BST and US initial jobless claims and producer prices out at 1330 BST.

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.